ORMP 10-Q: SEC filing

Oramed Pharmaceuticals

Filed with the SEC on Nov 12, 2026 · accession 0001213900-26-119064

ORMP filed a 10-Q (quarterly report) with the SEC on Nov 12, 2026. Oramed Pharmaceuticals filed its Q3 2026 Form 10-Q, reporting quarterly financial results including revaluation gains/losses on its Lifeward shares, warrants, and Initial Note, and disclosing a $1,000 SAFE investment in Hopec Pharma Ltd. The filing also notes subsequent events including a loan… The stock moved -2.4% by the first close after the filing.

Summary of the filing

Oramed Pharmaceuticals filed its Q3 2026 Form 10-Q, reporting quarterly financial results including revaluation gains/losses on its Lifeward shares, warrants, and Initial Note, and disclosing a $1,000 SAFE investment in Hopec Pharma Ltd. The filing also notes subsequent events including a loan agreement and restricted stock unit activity.

For details, click here →How to read a 10-Q →

Key details

SAFE investment in Hopec Pharma Ltd. (initial)$500

Maximum SAFE investment commitment in Hopec Pharma Ltd.$1K

Revaluation gain on Lifeward shares (nine months)$88

Revaluation gain on Lifeward warrants (nine months)$4K

Revaluation loss on Initial Note (nine months)$1K

Loss on conversion of Secured Promissory Note and additional note into Initial Note$1K

Revaluation loss on Lifeward shares (three months)$1K

Revaluation loss on Lifeward warrants (three months)$1K

Revaluation loss on Initial Note (three months)$1K

FilerOramed Pharmaceuticals Inc.

Safe investment targetHopec Pharma Ltd.

Equity investment (shares and warrants)Lifeward

Lender (subsequent event loan)MAR Bailey Avenue LLC

How ORMP stock reacted

Close before

$4.13

Nov 11, 2026

First close after

-2.42%

$4.03

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for ORMP, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ORMP?

Click here

Frequently asked questions

What did ORMP file with the SEC on Nov 12, 2026?

ORMP filed a 10-Q (SEC filing). Oramed Pharmaceuticals filed its Q3 2026 Form 10-Q, reporting quarterly financial results including revaluation gains/losses on its Lifeward shares, warrants, and Initial Note, and disclosing a $1,000 SAFE investment in Hopec Pharma Ltd. The filing also notes subsequent events including a loan agreement and restricted stock unit activity.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

How did ORMP stock react to this filing?

ORMP closed at $4.13 before the filing and $4.03 on Nov 12, 2026 (-2.42%).

Other ORMP SEC filings

Get alerts when ORMP files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

ORMP overview ORMP analysis ORMP news Latest SEC filings